92340-57-3

Basic information

• Product Name: 5-HYDROXY OMEPRAZOLE
• Synonyms: 4-Methoxy-6-[[(5-Methoxy-1H-benziMidazol-2-yl)sulfinyl]Methyl]-5-Methyl-3-pyridineMethanol SodiuM Salt;HydroxyoMeprazole SodiuM Salt;5-Hydroxy OMeprazole (~5% TriethylaMine as stabilizer);5-Methoxy-2-{[(5-hydroxymethyl-4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazole;5-HYDROXY OMEPRAZOLE;2-[(5-HYDROXYMETYL-4-METHOXY-3-METHYL-PYRIDIN-2-YL)-METHYLSULFO]-BENZIMIDAZOLE;4-Methoxy-6-[[(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-5-methyl-3-pyridinemethanol;Hydroxyomeprazole
• CAS NO: 92340-57-3
• Molecular Formula: C17H19N3O4S
• Molecular Weight: 361.42
• Product Categories: Pharmaceuticals;Isotopically Labeled Pharmaceutical Reference Standard;Various Metabolites and Impurities;Metabolites & Impurities;Sulfur & Selenium Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals
• Mol File: 92340-57-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 144-146?C
• Boiling Point: 656.3 °C at 760 mmHg
• Flash Point: 350.7 °C
• Appearance: /
• Density: 1.45 g/cm³
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 8.50±0.10(Predicted)
• Stability: Hygroscopic, Temperature Sensitive
• BRN: 8439890
• CAS DataBase Reference: 5-HYDROXY OMEPRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-HYDROXY OMEPRAZOLE(92340-57-3)
• EPA Substance Registry System: 5-HYDROXY OMEPRAZOLE(92340-57-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 2
• Hazardous Substances Data: 92340-57-3(Hazardous Substances Data)

Usage

Description

5-Hydroxy Omeprazole, also known as 5-Hydroxyomeprazole, is the main metabolite of Omeprazole, a proton pump inhibitor commonly used to treat acid-related disorders. It possesses the ability to bind covalently to the proton pump, thereby inhibiting gastric secretion and reducing the production of stomach acid.

Uses

Used in Pharmaceutical Industry:
5-Hydroxy Omeprazole is used as an anti-ulcerative agent for the treatment of acid-related disorders, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Its ability to inhibit gastric secretion and reduce stomach acid production helps alleviate symptoms and promote healing of the affected areas.
Additionally, 5-Hydroxy Omeprazole may be utilized in research and development for the discovery of new drugs targeting the proton pump, potentially leading to the creation of more effective treatments for acid-related disorders.

Upstream product

• 73590-58-6 omeprazole 

Relevant articles and documents

Evaluation of MTBH, a novel hesperetin derivative, on the activity of hepatic cytochrome P450 isoform in?vitro and in?vivo using a cocktail method by HPLC-MS/MS

1. 8-methylene-tert-butylamine-3′,5,7-trihydroxy-4′-methoxyflavanone (MTBH), a novel hesperidin derivative, has potential in the prevention of hepatic disease, however, its effects on cytochrome P450 isoforms (CYP450s) remains unexplored. The purpose was to investigate the effects of MTBH on the mRNA, protein levels, and activities of six CYP450s (1A2, 2C11/9, 2D2/6, 3A1/4, 2C13/19, and 2E1) in?vitro and in?vivo. 2. In vitro study, rat and human liver microsomes were adopted to elucidate the inhibitory effect of MTBH on six CYP450s using probe drugs. In vivo study, Sprague-Dawley male rats were treated with MTBH (25, 50, or 100 mg/kg for 28 consecutive days), phenobarbital (80 mg/kg for 12 consecutive days), or 0.5% CMC-Na solution (control group) by intragastric administration, then, the mRNA, protein levels and activities of liver CYP450s were analysed by real-time PCR, western blotting and probe-drug incubation systems, respectively. 3. The in?vitro study indicated that MTBH inhibits the activities of CYP3A1/4 and CYP2E1 in rat and human liver microsomes. In vivo data showed that MTBH inhibits mRNA, protein levels, and activities of CYP3A1 and CYP2E1 in medium- and high-dose MTBH groups. 4. MTBH has the potential to cause drug-drug interactions when co-administered with drugs that are metabolised by CYP3A1/4 and CYP2E1.

Prepare alkylene sulfonyl-1-H-benzimidazole derivatives

The invention relates to a method for preparing a sulfinyl-1-hydrogen-benzimidazole derivative. According to the invention, a 2-(1H-benzimidazole-2-methylmercapto)-4-hydroxy-pyridine derivative expressed in a general formula I is dissolved in a solvent, and under the effect of a catalyst and an additive, a hydrogen peroxide aqueous solution is used as an oxidizing agent for oxidizing reaction, so that the sulfinyl-1-hydrogen-benzimidazole derivative expressed in the general formula II (refer to the Specification) is prepared. The method has the advantages that the operation is simple, a catalyst with the harmful effect on a human body is not used, no pollution to the environment is caused, and the obtained product is higher in yield and purity, so that the method is suitable for industrialization scale production, and has important practical application value.